Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers

STRO-002 is a novel homogeneous folate receptor alpha (FolRα) targeting antibody–drug conjugate (ADC) currently being investigated in the clinic as a treatment for ovarian and endometrial cancers. Here, we describe the discovery, optimization, and antitumor properties of STRO-002. STRO-002 was gener...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaofan, Zhou, Sihong, Abrahams, Cristina L., Krimm, Stellanie, Smith, Jennifer, Bajjuri, Krishna, Stephenson, Heather T., Henningsen, Robert, Hanson, Jeffrey, Heibeck, Tyler H., Calarese, Daniel, Tran, Cuong, Yin, Gang, Stafford, Ryan L., Yam, Alice Y., Kline, Toni, De Almeida, Venita I., Sato, Aaron K., Lupher, Mark, Bedard, Kristin, Hallam, Trevor J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
MCT First Disclosures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890132/
https://www.ncbi.nlm.nih.gov/pubmed/36459691
http://dx.doi.org/10.1158/1535-7163.MCT-22-0322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890132/
https://www.ncbi.nlm.nih.gov/pubmed/36459691
http://dx.doi.org/10.1158/1535-7163.MCT-22-0322

Ejemplares similares